“Specifically Targeting Interleukin-13 with Tralokinumab Improved Sleep in Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Trials in Patients with Atopic Dermatitis” (2021) SKIN The Journal of Cutaneous Medicine, 5(1), p. s9. doi:10.25251/skin.5.supp.9.